# A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer

> **NCT07239466** · PHASE2 · RECRUITING · sponsor: **Tao Zhang** · enrollment: 25 (estimated)

## Conditions studied

- Rectal Cancer
- Radiotherapy
- Immunotherapy
- Chemotherapy

## Interventions

- **RADIATION:** Short-course radiotherapy
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **PROCEDURE:** TME surgery
- **DIETARY_SUPPLEMENT:** β-hydroxybutyrate

## Key facts

- **NCT ID:** NCT07239466
- **Lead sponsor:** Tao Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07239466

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07239466, "A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07239466. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*